← 治験一覧に戻る
思春期における破傷風トキソイド、ジフテリアトキソイド減量、無細胞百日咳ワクチン（ADACEL®）の追加接種に関する研究
基本情報
- NCT ID
- NCT01689324
- ステータス
- 完了
- 試験のフェーズ
- 第1/第2相
- 試験タイプ
- 介入
- 目標被験者数
- 43
- 治験依頼者名
- Sanofi
概要
This study is designed to assess the immunogenicity and safety of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (ADACEL®, Tdap vaccine) as a booster dose in adolescents in Japan. Primary Objective: * To assess the immunogenicity of Tdap (SP306) when administered as a single dose in Japanese adolescents Secondary Objective: * To assess the safety of Tdap vaccine when administered as a single dose in Japanese adolescents.
対象疾患
PertussisTetanusDiphtheria
介入
(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis(BIOLOGICAL)
依頼者（Sponsor）
Sanofi Pasteur, A Sanofi Company(INDUSTRY)